Posts

Showing posts from June, 2025

The Menopause Breakthrough: A New Biology to End Chronic Disease

Image
By RewriteBiology “What if everything we thought we knew about aging, menopause, and disease was wrong—and the key to preventing Alzheimer’s, diabetes, and heart disease was hiding in plain sight?” Why I Wrote This As a self-taught researcher, I've spent years studying the patterns of disease and blind spots in modern medicine. What I found was surprising: many chronic illnesses may stem from a misunderstood biological shift— menopause , in both men and women. This isn’t just about hormones. It’s about how a midlife shift marks the tipping point where pathogens overwhelm the immune system—leading to aging, neurological decline, and nearly all chronic diseases . From Crisis to Breakthrough Pharma is evolving, but current strategies still treat symptoms—not causes. What if Alzheimer’s , diabetes , and cancer all stem from the same failure in regeneration and immune control? What if it all starts around menopause? Menopause: The Overlooked Turning Point RewriteBiology r...

Has the AI Drug Discovery Hype Train Derailed? A Reality Check for Pharma and Biotech

Image
When smarter algorithms hit the wall of outdated biology In 2021, venture capitalists poured over $2 billion into AI-powered drug discovery startups. The hope was clear: artificial intelligence could compress a 10-year, multi-billion-dollar R&D cycle into a few years and a few million dollars. Companies like Recursion , Exscientia , and Insilico Medicine emerged as poster children for this new era, promising a revolution that would change the trajectory of pharmaceutical research forever. But fast forward to 2025, and the story looks much different. Stock prices are down. Investors are wary. M&A activity is heating up—not because of success, but because of pressure to survive. What happened? ⸻ 💡 AI Was a Tool, Not a Cure AI drug discovery promised efficiency: faster molecule generation, better hit prediction, and streamlined clinical trial design. In some areas—like protein structure prediction (e.g., AlphaFold)—it delivered. But the ...

Redefining Success: Why Pharma’s Billions Demand a New Biology

Image
Every year, pharmaceutical companies pour over $200 billion into drug research and development. It's a colossal investment, yet the outcome is often disheartening: less than 10% of drugs entering clinical trials ever make it to market. For an industry built on innovation, this staggering inefficiency begs a critical question: Are we searching for answers in the wrong places? At RewriteBiology, we firmly believe the answer is yes . Modern medicine, while groundbreaking in its time, operates on biological theories that now, we argue, limit true progress . These established frameworks dictate how we define disease, where we seek its causes, and how we attempt to intervene. But what if these foundational principles are incomplete—or, even worse, fundamentally flawed? By 2021, global pharmaceutical R&D spending reached approximately $200 billion. Looking forward, global pharmaceutical R&D spending is expected to continue its upward trajectory, with projections suggesti...

We Treat the Symptoms. The Body’s Fighting Something Deeper.

Image
When the Body Speaks, Are We Listening? Most people think of diagnosis as an answer — a label that explains the symptoms and tells you what to do next. But what if diagnosis is often just the first misunderstanding? In medicine, the body’s signals are too often interpreted as problems rather than messages. Inflammation, for example, is frequently treated as a threat — but it’s actually the immune system in action. It’s the body defending itself. Fever, fatigue, swelling — these aren’t random malfunctions. They’re targeted responses. Yet instead of asking why the body is reacting, many systems jump straight to how to suppress it. Consider cancer.   For years, tumors have been seen purely as dangerous growths. But research suggests that in some cases, they develop where chronic infection or immune dysfunction has quietly altered normal processes. Glioblastomas, pancreatic cancers, and certain lymphomas have been associated with imbalances in the microbiome and lingering path...

Beyond the Lecture Hall: Celebrating Biology’s Self-Taught Giants

Image
In the world of science, we often imagine brilliant minds forged in the hallowed halls of universities, meticulously earning their degrees and conducting research in state-of-the-art labs. And while formal education is undeniably vital, it’s a fascinating and inspiring truth that some of biology’s most profound breakthroughs came from individuals who carved their own paths, driven by an insatiable curiosity and a tireless dedication to understanding the natural world. These are the autodidacts , the self-taught giants who remind us that genius isn’t confined to a classroom. Their stories are a testament to the power of independent learning and the enduring human spirit of inquiry. Let’s dive into some incredible examples, with a special nod to those whose contributions directly impact our understanding of biological principles: ⸻ Michael Faraday: The Bookbinder Who Unlocked Electromagnetism While not strictly a “biologist” in the modern sense, Michael Faraday’s work on electromagnetism...